Denmarkʼs Xellia Pharmaceuticals inaugurated a USD 13 million expansion at its base in Budapest on Tuesday, state news wire MTI reported. Xellia added microbiology and chemical analytical laboratories, a product stability center and administrative offices next to its manufacturing plant in District X.
“The new facilities will play a significant role in Xellia’s global operational strategy, strengthening its product release and stability testing services for Active Pharmaceutical Ingredients and Finished Dosage Form (FDF) produced across the companyʼs other sites in the U.S., China and Denmark,” the drugmaker said in a press release. Xellia makes anti-infective treatments.
The investment has already created 40 jobs, but Xellia aims to raise headcount at the Centralized Laboratory Services operation to around 80 by 2019.
Minister of Foreign Affairs and Trade Péter Szijjártó and District X Mayor Zoltán Kovács joined the inauguration ceremony.
Xellia CEO Carl-Åke Carlsson said the company had expanded in Budapest because of the highly qualified local workforce.
Revenues of Xelliaʼs Hungarian unit rose 18% to HUF 5.5 billion last year, said Zsolt Németh, managing director of the local operation. This year, revenue growth is also targeted in double digits, he added.
Source: bbj.hu
